These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 2509418

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
    Edwards JR.
    New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH, Sheikh W, Nadler HL.
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [Abstract] [Full Text] [Related]

  • 4. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
    Schito GC, Sanna A, Chezzi C, Ravizzola G, Leone F, Molinari G, Menozzi MG, Pirali F.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
    [Abstract] [Full Text] [Related]

  • 5. In-vitro studies of meropenem.
    Jones RN, Barry AL, Thornsberry C.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():9-29. PubMed ID: 2808218
    [Abstract] [Full Text] [Related]

  • 6. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS.
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [Abstract] [Full Text] [Related]

  • 7. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C, Sirot D, Chanal M, Cluzel M, Sirot J, Cluzel R.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro activity of HRE 664, a penem antibiotic.
    Chin XN, Neu HC.
    Diagn Microbiol Infect Dis; 1990 Sep; 13(6):509-16. PubMed ID: 2279381
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B, Zühlsdorf M.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R, Mittermayer H, Feierl G, Allerberger F, Wendelin I, Hirschl A, Reisinger EC.
    Wien Klin Wochenschr; 1999 Jul 30; 111(14):549-54. PubMed ID: 10467641
    [Abstract] [Full Text] [Related]

  • 13. [In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic].
    Komoto A, Otsuki M, Nishino T.
    Jpn J Antibiot; 1996 Apr 30; 49(4):352-66. PubMed ID: 8786626
    [Abstract] [Full Text] [Related]

  • 14. In-vitro activity of meropenem against clinical isolates obtained in Canada.
    Clarke AM, Zemcov SJ.
    J Antimicrob Chemother; 1989 Sep 30; 24 Suppl A():47-55. PubMed ID: 2808216
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
    Harabe E, Kawai Y, Kanazawa K, Otsuki M, Nishino T.
    Drugs Exp Clin Res; 1992 Sep 30; 18(2):37-46. PubMed ID: 1644010
    [Abstract] [Full Text] [Related]

  • 16. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS, Hsueh PR, Lee WS, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Lam C, Chen RJ.
    Int J Antimicrob Agents; 2013 May 30; 41(5):457-62. PubMed ID: 23507415
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
    Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF.
    Antimicrob Agents Chemother; 2008 Dec 30; 52(12):4388-99. PubMed ID: 18779357
    [Abstract] [Full Text] [Related]

  • 19. Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom.
    King A, Boothman C, Phillips I.
    J Antimicrob Chemother; 1989 Sep 30; 24 Suppl A():31-45. PubMed ID: 2808214
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.